Long-acting RNAi therapeutics in hypertension: limitations of single-target AGT silencing and rational multi-target synergistic strategies
Hypertension affects over 1.3 billion people worldwide, fewer than 20% achieve adequate blood pressure (BP) control. Poor long-term BP management accelerates irreversible damage to target organs, highlighting the urgent need for novel therapeutic approaches. Small interfering RNAs (siRNAs) are synthetic oligonucleotide...